WebDisclosure
COMMUNIQUÉ DE PRESSE

par SARTORIUS STED BIO (EPA:DIM)

Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech

Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech

05-Jul-2023 / 13:55 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 Aubagne, July 5, 2023

 

 

Half-year liquidity contract statement for Sartorius Stedim Biotech

 

Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023:

 

  • 22,917 shares
  • € 4,751,581.19
  • Number of executions on buy side on semester: 5,887
  • Number of executions on sell side on semester: 5,674
  • Traded volume on buy side on semester: 253,847 shares for € 72,788,724.35
  • Traded volume on sell side on semester: 242,831 shares for € 70,620,474.51

 

As a reminder the following resources appeared on the last half year statement on 31 December 2022 on the liquidity account:

  • 11,901 shares
  • € 6,895,585.95
  • Number of executions on buy side on semester: 4,259
  • Number of executions on sell side on semester: 4,361
  • Traded volume on buy side on semester: 166,507 shares for € 56,282,984.47
  • Traded volume on sell side on semester: 174,847 shares for € 59,810,740.92

 

The following resources appeared on the liquidity account when the activity started:

 

  • 0 shares
  • € 10,000,000.00

 

 

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications safely, rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies. In fiscal 2022, the company generated sales revenue of around 3.5 billion euros. At the end of 2022, around 12,000 employees were working for customers around the globe.

 

Contact

Petra Müller

Head of Investor Relations

+49 (0)551.308.6035

Petra.mueller2@sartorius.com

 

Sartorius Stedim Biotech S.A.

Z.I. Les Paluds

Avenue de Jouques, CS 91051

13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00

Fax: +33.(0)4.42.84.56.19

www.sartorius.com

 

 

 

 

Buy side

Sell side

 

Number of executions

Number of shares

Traded volume in EUR

Number of executions

Number of shares

Traded volume in EUR

Total

5,887

253,847

72,788,724.35

5,674

242,831

70,620,474.51

02/01/2023

33

1,657

492,758.66

29

699

215,082.30

03/01/2023

40

1,700

504,033.00

31

1,500

446,505.00

04/01/2023

23

1,400

418,894.00

32

1,700

509,847.00

05/01/2023

32

1,800

542,988.00

29

1,300

393,796.00

06/01/2023

86

3,300

958,089.00

10

310

91,589.50

09/01/2023

13

   700

202,601.00

22

1,200

349,500.00

10/01/2023

34

1,700

495,856.00

27

1,800

528,408.00

11/01/2023

19

749

222,752.60

87

3,201

974,256.36

12/01/2023

29

1,600

502,608.00

68

2,900

915,501.00

13/01/2023

21

1,200

380,304.00

40

1,500

477,600.00

16/01/2023

5

1,000

323,100.00

63

2,300

746,902.00

17/01/2023

77

2,411

767,710.62

30

1,224

391,300.56

18/01/2023

35

1,629

523,153.35

44

1,876

605,591.56

19/01/2023

76

2,400

755,208.00

16

700

221,508.00

20/01/2023

40

1,550

482,251.50

31

1,600

499,408.00

23/01/2023

30

1,267

395,798.13

37

1,500

471,015.00

24/01/2023

58

2,403

749,736.00

17

800

253,104.00

25/01/2023

39

1,600

487,696.00

22

1,400

427,798.00

26/01/2023

12

500

159,500.00

85

4,900

1,577,065.00

27/01/2023

47

2,307

744,907.23

50

2,100

680,757.00

30/01/2023

39

1,700

551,905.00

66

2,120

690,780.80

31/01/2023

53

3,093

992,048.82

32

1,600

514,800.00

01/02/2023

37

1,500

481,200.00

62

2,900

936,787.00

02/02/2023

-

-

-

70

3,100

1,047,180.00

03/02/2023

64

2,800

957,012.00

67

2,700<

Voir toutes les actualités de SARTORIUS STED BIO